Despite Limitations, Gymnotic Delivery of Antisense Oligos Offers Benefits over Transfection
June 23, 2011
Despite Limitations, Gymnotic Delivery of Antisense Oligos Offers Benefits over Transfection
Gymnosis combines specifically modified antisense oligos with a cell's normal growth properties to achieve sequence-specific target knockdown without the need for transfection reagents or serum additives, according to its developers.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Isis Opposes Santaris Bid to Throw out Patent-Infringement Suit
March 29, 2012 / Gene Silencing News - Pfizer Aims to Head Off Court Hearing over Isis, Santaris Patent Dispute
April 11, 2013 / Gene Silencing News - Former Pfizer Exec Sees Oligo Drugs Becoming Major Platform Tech in Three Years
May 24, 2012 / Gene Silencing News - In Countersuit, Santaris Aims to Invalidate Isis Gapmer Patents
December 15, 2011 / Gene Silencing News - Santaris Pharma Says USPTO Upholds Key Antisense Patents
December 1, 2011 / Gene Silencing News